Last reviewed · How we verify
tafluprost/timolol
Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.
Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | tafluprost/timolol |
|---|---|
| Sponsor | Fondazione G.B. Bietti, IRCCS |
| Drug class | Prostaglandin analog / beta-blocker combination |
| Target | FP receptor (tafluprost); beta-2 adrenergic receptor (timolol) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tafluprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral pathway. Timolol blocks beta-2 adrenergic receptors in the ciliary body, reducing aqueous humor secretion. The combination provides additive intraocular pressure-lowering effects through complementary mechanisms.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Increased iris pigmentation
- Eyelash growth
- Bradycardia
- Fatigue
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. (PHASE4)
- Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tafluprost/timolol CI brief — competitive landscape report
- tafluprost/timolol updates RSS · CI watch RSS
- Fondazione G.B. Bietti, IRCCS portfolio CI